141 related articles for article (PubMed ID: 36186259)
1. Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters.
Mehan A; Anthony ML; Paul P; Syed A; Chowdhury N; Rao S; Hussain N; Ravi B
J Lab Physicians; 2022 Mar; 14(1):27-31. PubMed ID: 36186259
[No Abstract] [Full Text] [Related]
2. The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Meng Y; Wu H; Yao Y; Li R
Gland Surg; 2020 Dec; 9(6):2106-2115. PubMed ID: 33447561
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India.
Anthony ML; Chowdhury N; Mishra M; Tale S; Arathi K; Rao S
Cureus; 2022 May; 14(5):e25243. PubMed ID: 35755570
[TBL] [Abstract][Full Text] [Related]
4. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Kim HM; Lee J; Koo JS
BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.
Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J
Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study.
Ayoub NM; Fares M; Marji R; Al Bashir SM; Yaghan RJ
Breast Cancer (Dove Med Press); 2021; 13():603-615. PubMed ID: 34803400
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
[TBL] [Abstract][Full Text] [Related]
9. Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma.
Gupta A; Chandra S; Chauhan N; Arora A
J Lab Physicians; 2022 Dec; 14(4):491-496. PubMed ID: 36531539
[No Abstract] [Full Text] [Related]
10. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.
Hong M; Kim JW; Kim MK; Chung BW; Ahn SK
J Cancer; 2020; 11(24):7246-7252. PubMed ID: 33193888
[No Abstract] [Full Text] [Related]
12. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ
J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873
[TBL] [Abstract][Full Text] [Related]
13. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Li F; Ren Y; Wang Z
J Cancer Res Ther; 2018 Jan; 14(1):150-154. PubMed ID: 29516978
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of PD-L1 Expression in Invasive Breast Cancer: A Systematic Review and Meta-Analysis.
Cirqueira MB; Mendonça CR; Noll M; Soares LR; de Paula Carneiro Cysneiros MA; Paulinelli RR; Moreira MAR; Freitas-Junior R
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885199
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Doğukan R; Uçak R; Doğukan FM; Tanık C; Çitgez B; Kabukcuoğlu F
Eur J Breast Health; 2019 Oct; 15(4):235-241. PubMed ID: 31620682
[TBL] [Abstract][Full Text] [Related]
16. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
17. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
18. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
